- Overview
- SAR-bisPSMA
- SARTATE
- SAR-Bombesin
- Scientific Communications
- Access to Products
ASCO GU Symposium 2025
COBRA: Assessment of the efficacy of 64Cu-SAR-bisPSMA using histopathology as reference standard in patients with biochemical recurrence of prostate cancer following definitive therapy
Poster – ASCO GU Symposium 2025
CLARIFY: Positron emission tomography using 64Cu-SAR-bisPSMA in patients with high-risk prostate cancer prior to radical prostatectomy – a phase 3 diagnostic performance study
Poster – ASCO GU Symposium 2025
PSMA and Beyond 2025 Conference
COBRA: Assessment of the efficacy of 64Cu-SAR-bisPSMA using histopathology as reference standard in patients with biochemical recurrence of prostate cancer following definitive therapy
Poster – PSMA and Beyond 2025 Conference
AUA 2025 Annual Meeting
COBRA: Assessment of 64Cu-SAR-bisPSMA and standard of care prostate-specific membrane antigen Positron Emission Tomography in patients with biochemical recurrence of prostate cancer following definitive therapy
Poster – AUA 2025 Annual Meeting
COBRA: 64Cu-SAR-bisPSMA vs. follow-up SOC PSMA PET (subgroup analysis)
Moderated Poster Session Presentation – AUA 2025 Annual Meeting
ASCO 2025 Annual Meeting
COBRA: Assessment of the efficacy of 64Cu-SAR-bisPSMA using histopathology and standard of care imaging as reference standard in patients with biochemical recurrence of prostate cancer following definitive therapy
Poster – ASCO 2025 Annual Meeting
SECuRE: A dose escalation/expansion study to assess the anti-tumor efficacy of 67Cu-SAR-bisPSMA in patients with metastatic castration-resistant prostate cancer
Poster – ASCO 2025 Annual Meeting
SNMMI 2025 Annual Meeting
COBRA: Assessment of reader agreement for 64Cu-SAR-bisPSMA PET in patients with biochemical recurrence of prostate cancer following definitive therapy
Poster – SNMMI 2025 Annual Meeting
SECuRE: A dose escalation/expansion study to assess the anti-tumor efficacy of 67Cu-SAR-bisPSMA in patients with metastatic castration resistant prostate cancer
Poster – SNMMI 2025 Annual Meeting
NANETS 2025 Symposium
DISCO: Diagnostic performance of 64Cu-SARTATE compared to 68Ga-DOTATATE in patients with known or suspected neuroendocrine tumors
Presentation – NANETS 2025 Symposium
PCF Scientific Retreat 2025
64Cu-SAR-bisPSMA PET/CT Compared to SOC PSMA PET/CT in Biochemical Recurrence of Prostate Cancer: A Close-Up of the Phase II COBRA Trial
Presentation – PCF Scientific Retreat 2025
EANM 2024 Congress
COBRA: Assessment of safety and efficacy of 64Cu-SAR-bisPSMA in patients with biochemical recurrence of prostate cancer following definitive therapy
Presentation – EANM 2024 Congress
Treatment of metastatic castrate-resistant prostate cancer patient with two cycles of 67Cu-SAR-bisPSMA (8 GBq) leads to complete response (RECIST) and undetectable PSA level: A case report
Presentation – EANM 2024 Congress
SNMMI Annual Meeting 2024
SECuRE: A dose escalation/expansion study to assess the anti-tumor efficacy of 67Cu-SAR-bisPSMA in patients with metastatic castrate-resistant prostate cancer
Presentation – SNMMI 2024
SECuRE: A dose escalation/expansion study to assess the anti-tumor efficacy of 67Cu-SAR-bisPSMA in patients with metastatic castrate-resistant prostate cancer
Poster – SNMMI 2024
COBRA: Assessment of safety and efficacy of 64Cu-SAR-bisPSMA in patients with biochemical recurrence of prostate cancer following definitive therapy
Presentation – SNMMI 2024
COBRA: Assessment of safety and efficacy of 64Cu-SAR-bisPSMA in patients with biochemical recurrence of prostate cancer following definitive therapy
Poster – SNMMI 2024
COMBAT: A study of 64Cu-SAR-BBN and 67Cu-SAR-BBN for identification and treatment of GRPr-expressing metastatic castrate-resistant prostate cancer
Poster – SNMMI 2024
SABRE: Assessment of safety and efficacy of 64Cu-SAR-BBN in PSMA-negative biochemical recurrent prostate cancer patients
Poster – SNMMI 2024
ASCO Annual Meeting 2024
COBRA: Assessment of safety and efficacy of 64Cu-SAR-bisPSMA in patients with biochemical recurrence of prostate cancer following definitive therapy
Poster – ASCO 2024
CLARIFY: Positron emission tomography using 64Cu-SAR-bisPSMA in patients with high-risk prostate cancer prior to radical prostatectomy, a Phase 3 diagnostic study
Poster – ASCO 2024
PROPELLER – Comparison of PET/CT in Subjects with Confirmed Prostate Cancer Using 64Cu-SAR-bisPSMA and 68Ga-PSMA-11
Poster – SNMMI 2023
64Cu SAR bisPSMA (PROPELLER) Positron Emission Tomography (PET) Imaging in Patients with Confirmed Prostate Cancer
Poster – ASCO 2023
Positron Emission Tomography of Patients with Confirmed Prostate Cancer Using 64Cu-SAR-bisPSMA: results from PROPELLER
Poster – ASCO GU 2023
[64Cu]Cu-SAR-Bombesin ([64Cu]Cu-SAR-BBN) PET-CT for the detection of biochemically recurrent PSMA-PET negative prostate cancer: a case series
Poster Abstracts – RANZCR ASM 2022
